KRH-3955 hydrochloride

KRH-3955 hydrochloride 是一种具有口服活性的 CXCR4 拮抗剂,可抑制 SDF-1α 与 CXCR4 的结合(IC50 为 0.61 nM),同时也是高效、选择性的 X4 HIV-1 抑制剂(EC50 为 0.3 至 1.0 nM)。
产品编号: MS-U76285 CAS No.: 2253744-59-9 分子式: C28H48Cl3N7 分子量: 589.09
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

KRH-3955 hydrochloride 是一种具有口服活性的 CXCR4 拮抗剂,可抑制 SDF-1α 与 CXCR4 的结合(IC50 为 0.61 nM),同时也是高效、选择性的 X4 HIV-1 抑制剂(EC50 为 0.3 至 1.0 nM)。

生物实验数据

生物活性 KRH-3955 hydrochloride is an orally active CXCR4 antagonist that inhibits the binding of SDF-1α to CXCR4 with an IC50 of 0.61 nM and is also a potent and selective X4 HIV-1 inhibitor with an EC50 of 0.3 to 1.0 nM.
IC50 & Target SDF-1α-CXCR4:0.61 nM (IC50), X4 HIV-1 (NL4.3):0.3-1.0 nM (EC50)
体外研究
(In Vitro)

KRH-3955 inhibits the replication of NL4-3 in activated peripheral blood mononuclear cells (PBMCs) from eight different donors with the EC50 ranging from 0.23 to 1.3 nM.
KRH-3955 inhibits the infection of CD4/CXCR4 cells by these recombinant drug-resistant viruses, including viruses resistant to PIs, NRTIs, or NNRTIs, multidrug-resistant viruses and T20-resistant viruses, with the IC50 ranging from 0.4 to 0.8 nM.
KRH-3955 (10-100 nM) inhibits the SDF-1α-induced increase in the intracellular Ca2+ concentration in a dose-dependent manner.
KRH-3955 (0.1-1000 nM) binding sites are located in a region composed of all three extracellular loops (ECLs) of CXCR4.
KRH-3955 (10 nM) has a strong binding affinity for CXCR4 and a slow dissociation rate.
KRH-3955 inhibits MAb 12G5 binding to CXCR4 mutants, with the IC50 ranging from 0.5 to 14.1 nM.

体内研究
(In Vivo)

KRH-3955 (10 mg/kg; a single p.o.) efficiently suppresses X4 HIV-1 infection in hu-PBL-SCID mice.
KRH-3955 (10 mg/kg; a single p.o.) exhibits moderate oral bioavailability (25.6%) and Cmax (86.3 ng/mL).
KRH-3955 (10 mg/kg; a single i.v.) exhibits terminal elimination half-lives (99 h) due to high plasma clearance (3.9 liters/h/kg) combined with large volumes of distribution (374 liters/kg).

Animal Model: C.B-17 SCID mice engrafted with human PBMCs and injected with infectious X4 HIV-1 (NL4-3)
Dosage: 10 mg/kg
Administration: A single p.o. administration
Result: Four of five mock-treated mice were infected whereas only one of five mice treated with KRH-3955 was infected.
Animal Model: Male Sprague-Dawley rats
Dosage: 10 mg/kg (Pharmacokinetic Analysis)
Administration: A single p.o. or i.v. administration
Result: Well absorbed and the absolute oral bioavailability in rats was calculated to be 25.6%.
The half time (T1/2) of 99.0±13.1 h.
Stable in human hepatic microsomes, and no significant inhibition of CYP450 liver enzymes by this compound was observed.
性状 固体
颜色 White to light yellow

化学信息

分子量 589.09
分子式 C28H48Cl3N7
CAS No. 2253744-59-9

储存&溶解度

储存方式

4°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础